# REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors

> **NCT06710548** · NA · RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 240 (estimated)

## Conditions studied

- Ovarian Cancer
- Advanced Ovarian Carcinoma
- Fallopian Tube Carcinoma
- Primary Peritoneal Cancer
- PARP Inhibitor
- Fatigue Related to Cancer Treatment
- Fatigue in Cancer Survivors

## Interventions

- **BEHAVIORAL:** REVITALIZE Intervention
- **BEHAVIORAL:** Educational Materials

## Key facts

- **NCT ID:** NCT06710548
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-17
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-01-31
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06710548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06710548, "REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06710548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*